Abiomed, Inc. (NASDAQ: ABMD) today announced that it has priced its offering of common stock at $13.75 per share. The offering consists of 5,000,000 shares of common stock, all of which are being sold by Abiomed. The net proceeds to Abiomed from the offering are expected to be approximately $63.6 million, after deducting underwriting discounts and commissions and estimated offering expenses. The underwriters have been granted an option to purchase up to an additional 750,000 shares of Abiomed’s common stock to cover over-allotments, if any.
The offering is being managed by Morgan Stanley & Co. Incorporated and UBS Securities LLC as joint book-running managers.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities. The offering of shares of common stock may be made only by means of a prospectus supplement and the accompanying prospectus. Copies of the prospectus supplement and the accompanying prospectus, when available, can be obtained by contacting the Prospectus Department of: Morgan Stanley, 180 Varick Street, New York, NY, 10004, or by email at prospectus@morganstanley.com; or UBS Investment Bank, 299 Park, New York, NY,10171, (212) 821-3000.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. Abiomed currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. The Company also developed the AbioCor® Implantable Replacement Heart. In Europe, Abiomed offers the Impella® LP2.5, Impella® LP5.0, Impella® LD, the Impella® RD and an Intra-Aortic Balloon and the iPulse™ console under CE Mark approval. The Impella® 5.0 and 2.5 are investigational devices limited by Federal Law solely to investigational use in the United States. Other Impella devices and the iPulse™ combination console system are not yet available for sale in the United States. For additional information please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
Statements in this press release concerning the expected public offering are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially. Such factors that could cause actual results to differ materially from any forward-looking statements made by Abiomed include, among others, the risk that the planned public offering will not be completed, uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company’s filings with the Securities and Exchange Commission, including the Company’s most recently filed quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
